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Introduction
In recent years, the introduction of array-CGH
(comparative genomic hybridization) has greatly
improved the ability to analyze the human genome
and is quickly revolutionizing the definition of mole-
cular diagnostics in patients with “chromosomal”
phenotype (intellectual disability, dysmorphic fea-
tures, congenital anomalies) and normal karyotype(1-4).
Array-CGH analysis has led to the discovery of sev-
eral submicroscopic genomic variants (duplications
and deletions), which are responsible for a lot of
syndromes associated with global developmental
delay and congenital malformations(5). Today we are
showing that many of those patients who, in the
past, received a clinical diagnosis of sporadic auto-
somal recessive syndrome or de novo autosomal
dominant syndrome, are actually carriers of cryptic
chromosomal imbalance responsible for their condi-
tion(6-8). Many studies report that about 15% of these
patients have a cryptic chromosomal anomaly,
detected by array-CGH with a resolution of 1Mb. 
All these conditions play a very important
role in determining morbidity and mortality rates,
especially in neonatal age, when many other risk
factors (prematurity, twinning, nosocomial infec-
tions, chemical mediators, …)(16-22). May add their
cumulative effect influencing short and long-term
outcome. Array-CGH also offer the possibility to
identify de novo pathological chromosomal aberra-
tions), by copy number variations (CNVs) in
excess or in defect, compared to a control popula-
tion. These CNVs are associated not only with spe-
cific clinical features, but also with an increased
susceptibility to the development of complex dis-
eases such as schizophrenia, autism and autoim-
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ABSTRACT
Several studies have shown  the importance of Copy Number Variations (CNVs) in the etiology of autism spectrum disorders
(ASDs). In particular, a CNV of about 550 Kb in 16p11.2 has recently been described in up to 1% of autistic patients. Deletions and
mutual duplications of this region have also been associated with neurocognitive abnormalities, impairment in social interaction,
language delay, congenital anomalies, minor dysmorphisms, respectively micro- and macrocephaly.
We report 4 patients with 16p11.2 microdeletion and one patient with 16p11.2 microduplication. All patients have language
delay and dysmorphic features, even if there is no common phenotype.
Even in our experience, the identification by array-CGH of cryptic chromosomal abnormalities and de novo pathological
CNVs helped us to make a more accurate genotype-phenotype correlation and to establish individualized diagnostic and therapeu-
tic strategies.
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mune diseases, thus changing the perception of
structural genomic variation and causes of
Mendelian diseases.
Several studies show the importance of CNVs
in the etiology of autism spectrum disorders
(ASDs). In particular, a CNV of about 550 Kb in
the 16p11.2 region has recently been described in
numerous studies. 16p11.2 microdeletion was ini-
tially reported to occur in up to 1% of autistic
patients(23,24). Further studies associated 16p11.2
microdeletion syndrome with delayed language
development (with particular involvement of the
expressive sphere), intellectual disability, impair-
ment in social interaction and facial dysmorphism.
Furthermore, deletions of this region seem to be
associated with a form of early-onset obesity, due to
haploinsufficiency of the SH2B1 gene, which is
involved in leptin and insulin signaling, and with
congenital anomalies like minor cardiac malforma-
tions, hemivertebrae and syringomyelia.
We report 4 patients with 16p11.2 microdele-
tion and one patient with 16p11.2 microduplication.
Our objective is to contribute to the definition of
the phenotype associated with 16p11.2 CNVs.
Materials and methods
We have carried out testing of the peripheral
blood of our patients and their parents, followed by
DNA extraction using QIAamp DNA Blood Midi
Kit (Qiagen). Array-CGH analysis was initially per-
formed in the DNA of the proband, then we con-
firmed the alteration with FISH (fluorescence in
situ hybridization) or Dye-swap. FISH was per-
formed using bacterial artificial chromosome
(BAC) probes, that contain inserts of about 200 Kb.
After that, the rearrangement has been looked for in
the parents’ DNA by array-CGH, in order to define
a de novo or inherited origin.
Case reports
Patients carrying a 16p11.2 deletion
Patient 1 is a 3-year old child. He is the fifth
son of healthy, non-consanguineous parents, born at
37 weeks of gestation by cesarean section. He was
reported to be small for gestational age (SGA), with
a birth weight of 2120 g, a birth length of 45 cm
and a head circumference of 34 cm. 
He has mild dysmorphic features: short and
down-slanted palpebral fissures, anteverted nares
and a broad nasal bridge. 
Neuropsychiatric evaluation revealed global
developmental delay. 
Cardiac and renal ultrasounds were reported
normal. 
He has a normal male karyotype (46, XY), but
array-CGH analysis showed a 16p11.2 deletion of
about 524 Kb (Figure 1). Array-CGH analysis
showed normal copy numbers in both parents.
Patient 2 is a 4-year old boy, the first child of
non-consanguineous parents. He was born at term
by cesarean delivery, with a birth weight of 3450 g.
He has a severe speech delay, behavioural disorder
and obesity. 
His family history is positive for speech retar-
dation. 
His karyotype was normal and array-CGH
analysis showed a deletion of about 524 Kb in
16p11.2 region. Array-CGH in his parents con-
firmed a de novo deletion.
Patient 3 is a 4-year old child. He is the first
child of non-consanguineous parents, born at 40
weeks of gestation after a normal pregnancy and
delivery. His birth weight was 3870 g, birth length
was 51 cm and head circumference 36 cm. 
At birth he presented dysmorphic features, so
a karyotype analysis (46, XY) was immediately
performed. 
He also had bilateral cryptorchidism, for
which he underwent surgery at the age of 3 years.
Neuropsychiatric evaluation revealed a severe
expressive language disorder, while neuromotor
development was normal. 
Array-CGH analysis showed a 446 Kb
16p11.2 deletion, that was confirmed to be de novo.
Patient 4 is a 6-year old boy, the third child of
non-consanguineous parents. He was born at term by
cesarean section; during pregnancy intrauterine
growth restriction (IUGR) was detected. At birth, he
was reported to be small for gestational age, with a
birth weight of 2530 g, a birth length of 44.8 cm and
a head circumference of 31 cm (all measurements
below the 3° centile). Despite this, his general condi-
tion was quite good. He also had cleft palate, for
which he underwent surgery at the age of 1 year. 
On examination at the age of 21 months, he
had low weight (7.400 kg), short length (71 cm)
and small head circumference (45.3 cm): these val-
ues confirmed his growth retardation. 
His development was delayed and, in particu-
lar, a severe expressive language disorder was
revealed. 
Physical examination also showed dysmorphic
features: short palpebral fissures, prominent fore-
head, sparse and thin hair, dysplastic ears, clin-
odactyly of the fifth finger and hyperlaxity.
Cardiac, brain and abdominal ultrasounds were nor-
mal. Considering his growth retardation, screening
for celiac disease, sweat testing for Cystic Fibrosis
and x-ray of the hand were performed, but all
results were negative.
Array-CGH analysis revealed a deletion of about
520 Kb in the 16p11.2 region. Array-CGH analysis
showed normal copy numbers in both parents.
Patient carrying a 16p11.2 duplication
Patient 5 is a 14-year old boy, born as the sec-
ond child of healthy, non-consanguineous parents.
Neuropsychological examination at the age of 9
years indicated mild mental retardation and speech
delay. His gross and fine motor development were
delayed too. 
On physical examination, we detected some
dysmorphisms: elongated facies, protruding ears,
prominent nose and hyperlaxity. 
Cardiac ultrasounds and a brain MRI were
normal. EEG showed some abnormalities without
overt seizures.
Karyotype and Fragile X syndrome analysis
were also normal. Array-CGH analysis showed a
16p11.2 duplication of about 520 Kb (Figure 2).
Performing array-CGH in both parents, we revealed
that the rearrangement was de novo.
Discussion
16p11.2 deletion/duplication syndrome is a
good example of the utility of array-CGH in the
identification and definition of new rare syndromes.
Thanks to the use of this technique in the study of
cohorts of individuals with intellectual disability,
speech delays and/or autism spectrum disorders,
and with a normal karyotype, today we know the
role of chromosome 16 CNVs in the etiology of
these disorders. Analysis of our patients revealed
that 4 children with the microdeletion and one child
with the microduplication all have language delay
and dysmorphic features, even if there is no com-
mon model. Two patients with deletion were report-
ed to be small for gestational age (SGA), and one of
them also had postnatal growth retardation. Only
one patient presents behavioral problems and obesi-
ty. Furthermore, two patients have, respectively,
bilateral cryptorchidism and cleft palate. In addition
to these features, the only patient with microdupli-
cation has mild mental retardation, motor delay and
EEG abnormalities (Table 1).
This study confirms the findings of the most
recent data in the literature, namely that typical fea-
tures of the syndrome are a variable degree of lan-
guage delay and dysmorphisms.  As seen, other
clinical manifestations can be associated. However,
in none of our patients did we find the congenital
anomalies described in association with 16p11.2
deletion (cardiac malformations, hemivertebrae and
syringomyelia).
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We have also focused on the molecular genetic
pathogenesis of these rearrangements. 16p11.2
CNVs are mediated by recombination between
flanking 147 Kb low-copy repeat sequences (LCR)
with 99.5% sequence identity(18-22).
Low-copy repeat elements, or duplicons, are
blocks of a few repeated sequences, with very high
mutual homology (from 90% to 100%) and large
hundreds of kilobases (200-400 Kb). They are
throughout the genome, representing up to 5% of
the human genome, and are located in subtelomeric
and pericentromeric regions. A high degree of
homology, extension, orientation and mutual dis-
tance between two or more duplicons make the
region in which they are present unstable. So they
can lead to misalignment of chromosomes or chro-
matids and mediate nonallelic homologous recom-
bination (NAHR) that can result in unequal cross-
ing-over(23). This will result in various genomic
rearrangements, including inversions, transloca-
tions, duplications or deletions, as in the case of
16p11.2 microdeletion/microduplication.
In 16p11.2 region 27 genes are included, 8 of
which have been identified as possible candidates
in the genesis of the syndrome. Despite this, how
deletion or duplication of these genes results in the
clinical symptoms of the syndrome is unknown. In
particular, the genes studied are:
• ALDOA: aldolase A, fructose-bisphosphate;
• DOC2A: coding for proteins of the synaptic
vesicles;
• HIRIP3: HIRA-interacting protein 3,
involved in gene transcription control;
• MAPK3: mitogen-activated protein kinase 3,
a cell cycle regulator (this gene in not included in
524 Kb and 446 Kb regions identified in our
patients);
• MAZ: MYC-associated zinc finger protein;
• PPP4C: protein phosphatase 4, catalytic sub-
unit;
• SEZ6L2: seizure related 6 homolog (mouse)-
like 2;
• TAOK2: TAO kinase 2, involved in cellular
signaling and apoptosis.
The most studied gene was SEZ6L2, varia-
tions in which were originally associated with
autism(24). Kumar and, subsequently, Konyukh(25)
came to the conclusion that there is insufficient evi-
dence to establish the role of this gene in the onset
of autism spectrum disorders or related disorders.
Further studies are needed to understand how the
loss or the duplication of this critical region can
cause this particular phenotype.
Conclusions
Even in our experience, the identification of
cryptic chromosomal abnormalities helped us to
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Common phenotype Patient Patient Patient Patient Patient
1 2 3 4 5
Dysmorpich features + + + + +
Language delay + + + + +
Learning disability/
Intellectual disability - - - - +
Social impairment - + - - -
Seizures/EEG abnormalities - - - - +
Obesity - + - - -
Cardiac malformations - - - - -
Hemivertebrae - - - - -
Syringomyelia - - - - -
Other features SGA - Cryptorchidism
SGA, postnatal
growth retardation,
cleft palate
Motor delay
Table 1: Clinical features of 16p11.2 microdeletion/microduplication syndrome.
make a more accurate genotype-phenotype correla-
tion (linked not only to the type of chromosome
involved in altering, but also to the extension of the
region). We are  also able to plan an appropriate
global evaluation of the patient and organize a tar-
geted follow-up, in order to prevent all possible
manifestations. It is clear that, the early we make
diagnosis, the better the patient outcome.
The identification of the cryptic anomaly
responsible for the phenotype allows us to carry out
the study of parents to detect possible cryptic bal-
anced chromosomal translocations. It is possible,
therefore, to perform genetic counseling, indicating
a low risk of recurrence in de novo cases (possible
gonadal mosaicism) and a higher risk in familial
forms. Having also confirmed all cryptic chromoso-
mal abnormalities by FISH allows us to offer the
possibility of molecular cytogenetics prenatal diag-
nosis.
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